Research programme: G protein-coupled receptor modulators - ASINEX/BiovitrumAlternative Names: Metabolic disorders therapeutics - ASINEX/Biovitrum
Latest Information Update: 09 Mar 2009
At a glance
- Originator ASINEX; Biovitrum
- Mechanism of Action G protein-coupled receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 09 Jul 2007 Preclinical development is ongoing